Kissei Pharmaceutical Co., Ltd.

Akira Iyobe

Masayuki Isaji

Hideki Fujikura

Toshihiro Nishimura

Masahiro Hiratochi

Kenji Katsuno

Minoru Fujioka

Hiromu Harada

Kazuya Tatani

Shigeru Yonekubo

Hirotaka Teranishi

Masahiko Uchida

Arao Ujiie

Koji Kamata

The present invention provides crystals of 2-(4-methoxybenzyl)phenyl 6-O-ethoxycarbonyl-&#x3b2;-D-glucopyranoside, pharmaceutical compositions containing the same and their uses, which exhibit excellent SGLT2 inhibitory activities, and are useful for treating or preventing diseases associated with hyperglycemia.

Crystals of glucopyranosyloxybenzyl benzene derivative

The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein Rrepresents a hydrogen atom or a lower alkyl group; one of Qand Trepresents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and Rrepresents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.

Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof

The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula:wherein Rrepresents a hydrogen atom or a lower alkyl group; one of Qand Trepresents a group represented by the general formula:while the other represents a lower alkyl group or a halo(lower alkyl) group; and Rrepresents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.

Piperidino-3,4-dihydrocarbostyril compounds represented by the formula: ##STR1## wherein R.sup.1 represents a hydroxy group or an acyloxy group having 2 to 11 carbon atoms; one of R.sup.2 and R.sup.3 represents a nitro group, a cyano group, an alkoxycarbonyl group having 2 to 7 carbon atoms, an alkyl group having 1 to 4 carbon atoms, a haloalkyl group having 1 to 3 carbons atoms, or a halogen atom, and the other represents a hydrogen atom; and pharmaceutically acceptable salts thereof, exhibit platelet aggregation inhibiting activity and thus being useful as therapeutic agents for the prevention or treatment of cerebral ischemic disorders and arterial ischemic disorders.

Piperidino-3,4-dihydrocarbostyril compounds

Growing community of inventors

Nagano, Japan

Akira Iyobe